| | | Total no. of patients (%) | No. of male patients (%) | No. of female patients (%) |
| | No. of patient (%) | 1,820 | 1,040 (57.1) | 780 (42.9) | | Person-year at risk | 8,013 | 4,410 | 3,603 | | Age at diagnosis | 59.5 ± 17.5 | 61.0 ± 16.7 | 57.5 ± 18.3 | | Median follow-up (year) | 4.4 ± 3.0 | 4.2 ± 3.0 | 4.6 ± 3.2 | | Outpatient visits, (past 1 year) | | ≦5 visits, n (%) | 87 (4.8) | 64 (6.2) | 23 (2.9) | | 6–10 visits, n (%) | 205 (11.3) | 125 (12.0) | 80 (10.3) | | >10 visits, n (%) | 1528 (84.0) | 851 (81.8) | 677 (86.8) | | Income | | Dependent, n (%) | 420 (23.1) | 179 (17.2) | 241 (30.9) | | 0–624 US dollars, n (%) | 454 (24.9) | 323 (31.1) | 131 (16.8) | | 625−1,374 US dollars, n (%) | 803 (44.1) | 432 (41.5) | 371 (47.6) | | >1,375 US dollars, n (%) | 143 (7.9) | 106 (10.2) | 37 (4.7) | | Urbanization | | Level 1, n (%) | 985 (54.1) | 566 (54.4) | 419 (53.7) | | Level 2, n (%) | 629 (34.6) | 364 (35.0) | 65 (8.3) | | Level 3, n (%) | 175 (9.6) | 95 (9.1) | 80 (10.3) | | Level 4, n (%) | 31 (1.7) | 15 (1.4) | 16 (2.1) | | Charlson comorbidity index score | | 0–2, n (%) | 434 (23.8) | 217 (20.9) | 217 (27.8) | | 3-4, n (%) | 372 (20.4) | 210 (20.2) | 162 (20.8) | | ≧5, n (%) | 613 (33.7) | 613 (58.9) | 401 (51.4) | | No. of comorbidities (%) | | Diabetes mellitus, n (%) | 537 (29.5) | 306 (29.4) | 231 (29.6) | | Hypertension, n (%) | 1100 (60.4) | 672 (64.6) | 428 (54.9) | | Chronic kidney disease, n (%) | 557 (30.6) | 342 (32.9) | 215 (27.6) | | Coronary artery disease, n (%) | 718 (39.5) | 420 (40.4) | 298 (38.2) | | Dyslipidemia, n (%) | 637 (35.0) | 377 (36.3) | 260 (33.3) | | Chronic liver disease, n (%) | 624 (34.3) | 383 (36.8) | 241 (30.9) | | Autoimmune disease, n (%) | 240 (13.2) | 115 (11.1) | 125 (16.0) | | Drug abuse, n (%) | 46 (2.5) | 35 (3.4) | 11 (1.4) |
|
|
